Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil
(AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active
comparator Timolol Maleate Ophthalmic Solution, 0.5%.